MedTrace Logo

Phase III Trial of High Dose vs. Standard Dose Vit D2 With Docetaxel in Met Breast ca

NCT00944424 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2011-12-13

No results posted yet for this study

Summary

Randomized phase III trial to determine the effectiveness of High dose versus Standard dose of Vitamin D2 (Ergocalciferol) given with Docetaxel in patients with metastatic breast cancer

Conditions

Interventions

DRUG

Docetaxel + High dose Vitamin D2

Docetaxel + High dose Vitamin D2

DRUG

Docetaxel + Standard dose Vitamin D2

Docetaxel + Standard dose Vitamin D2

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    lead OTHER

Principal Investigators

  • Taher Al-Tweigeri, MD · KFSHRC

  • Dahish Ajarim, MD · KFSHRC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Kuwait
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944424 on ClinicalTrials.gov